CT26.MtC3, a new preclinical model to investigate immune resistance in metastatic colorectal cancer.

Both cell lines displayed overlapping survival curves, with no significant difference in colony-forming ability at any dose tested, despite a slight trend for CT26.MtC3 to be more sensitive (Fig. 4 H).

also in 4,078 other papers

However, we observed a highly significant decrease in the proportion of CD8 + T cells within the immune cell population in CT26.MtC3 tumors (median, 4.6%±1.71) compared to CT26.WT tumors (median, 10.3%±1.29), representing a roughly 2-fold reduction.

also in 132,142 other papers

In contrast, mitochondrial mass, as assessed by MitoTracker staining, showed a downward trend (− 20.6%±7.7, MFI), although this difference did not reach statistical significance (Fig. 4 F).

also in 111,027 other papers